- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- U.S. investors
- Regulated information in France
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Ethics and transparency
- Preserving the environment
- ‘LE HUB’ eMAG
Sanofi, a global life sciences company
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 100,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
Medicine has made great progress in the last century. The average life expectancy of people worldwide has doubled in that time, thanks in large measure to the development of innovative treatments for serious diseases.
At Sanofi, we have a clear and resolute line for action: to contribute to the continuous advancement of health. As a company, and as individuals, Sanofi and its talented employees have always striven to advance the cause of health by developing treatments that prevent and treat diseases, while enhancing access to healthcare for the people around the world.
The expertise we have developed along the way has had a profound effect, particularly in the developing world. We have developed the first vaccine for the dengue virus, which infects 390 million people each year, and whose range is expanding due to climate change. Since the beginning of the year, first vaccinations campaigns have started in the Philippines. Thanks to systematic vaccination campaigns, we are close to eradicating polio; while over the last decade, sleeping sickness treatments have saved more than 180,000 lives. In addition, we provide innovative treatments for global killers like diabetes and cardiovascular diseases.
Yet, there is much to be accomplished. A third of the world’s population still has no access to healthcare. And providing health products and services is just one part of the solution to tackle health inequalities that threat human development. As a responsible leader, we must adapt the way we operate to meet our commitment to health.
We also must continue to uncover innovations to be shared widely among those in need. To do so, we know that the solution will emerge by listening to our stakeholders, and with a collaborative approach. For that, we partner with the Bill & Melinda Gates Foundation, the GAVI Alliance and the World Health Organization, amongst others.
Finally, our commitment to health goes beyond medicine, in part through our corporate responsibility approach and our dedication to make a real difference in the lives of people every day.
Research starts by understanding science and transforming progress, into medical innovations that meet patients’ needs. To achieve this and facing the complexity of human diseases, we leverage our in-house skills and collaborate with the wider scientific community.
In 2015, we launched 3 pioneer treatments:
- Toujeo® (Insulin glargine 300 U/ml) in diabetes
- Praluent® (alirocumab)1 against hypercholesterolemia
- Dengvaxia®, the first ever vaccine against dengue fever
We expect to have 3 more major launches by 2020 in the field of asthma and atopic dermatitis (dupilumab), rheumatoid arthritis (sarilumab), and diabetes (Lixilan).
Our industrial network to ensure high quality and maximum safety
At Sanofi, we have strengthened the efficiency of our industrial resources and increased our presence in emerging countries, with a unique position with 87 industrial sites in 38 countries that enables an offer adapted to region-specific characteristics and responsiveness to tenders.
Regardless of where our treatments are manufactured, our industrial network provides both healthcare professionals and patients with high quality and maximum safety.
We are experts at producing and distributing our healthcare solutions, whether a cold chain is required or not. Our flexible industrial network enables us to fully master medicine and vaccine lifecycle and control their quality.
From the plant to the patient: a medicine’s journey:
To protect patient, ensure product quality and preserve trust in the supply chain we also have a dedicated team that works day in day out coordinating company-wide efforts to fight attempts to counterfeit Sanofi’s products. Fighting counterfeit drugs represents a substantial public health challenge as international organizations consider that counterfeiting involves, on average, 10% of the global pharmaceutical market and counterfeiters increasingly use sophisticated means to produce fake medicines. At Sanofi, we address counterfeiting from the outset when defining packaging for products, incorporating anti-counterfeiting techniques into new product launches. We have developed security labels, packaging with tamper-evident technology and data matrix codes to identify the contents.
From drug production to fight against counterfeit medicines:
Our industrial network, know-how and teams, thanks to a high quality and safety approach, deliver health solutions to millions of individuals across the globe.
Access to healthcare
Our Access to Medicines approach is on the ground, with long-lasting partners in disease areas where we have a recognized expertise: malaria, tuberculosis, neglected tropical diseases, epilepsy and mental illness. To promote access to healthcare to the greatest number, we developed a holistic approach that includes research on adapted drugs, development of preferential pricing policies in low-developed countries to make our solutions affordable, while developing information, education and communication programs to train healthcare professionals. In 2015, 280 programs have been implemented within the communities the most in need. 55 million patients received diagnosis, vaccination, treatment and targeted more than 260 million people through awareness campaigns.
- Praluent® is developed and commercialized in collaboration with Regeneron Pharmaceuticals, Inc